CO4910139A1 - Formulaciones en particulas revestidas - Google Patents
Formulaciones en particulas revestidasInfo
- Publication number
- CO4910139A1 CO4910139A1 CO97055063A CO97055063A CO4910139A1 CO 4910139 A1 CO4910139 A1 CO 4910139A1 CO 97055063 A CO97055063 A CO 97055063A CO 97055063 A CO97055063 A CO 97055063A CO 4910139 A1 CO4910139 A1 CO 4910139A1
- Authority
- CO
- Colombia
- Prior art keywords
- copolymer
- olanzapine
- formulations
- coated particles
- ester
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Una formulación oral sólida que comprende olanzapina comoingrediente activo y uno o más excipientes farmacéuticamente aceptables en donde la olanzapina va revestida con un polímero seleccionado del grupo conformado por alcohol cetílico, cera de ésteres cetílicos, cera carnauba, shellac, cera de abejas, estearato de magnesio, hidroxipropilmetilcelulosa, hidroxietilcelulosa, metilhidroxietilcelulosa, carboximetil-celulosa sódica, hidroxipropilcelulosa, polivinilpirrolidona, copolímero acido-éster dimetilaminometilmetacrilatometilacrilato, copolímero etilacrilato- metilmetacrilato, metilcelulosa, y etilcelulosa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2663396P | 1996-09-24 | 1996-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4910139A1 true CO4910139A1 (es) | 2000-04-24 |
Family
ID=21832952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO97055063A CO4910139A1 (es) | 1996-09-24 | 1997-09-22 | Formulaciones en particulas revestidas |
Country Status (21)
Country | Link |
---|---|
US (1) | US20010020032A1 (es) |
EP (1) | EP0830858A1 (es) |
JP (1) | JP2001501207A (es) |
KR (1) | KR20000048540A (es) |
CN (1) | CN1230883A (es) |
AR (1) | AR009802A1 (es) |
AU (1) | AU719788B2 (es) |
BR (1) | BR9713215A (es) |
CA (1) | CA2266448A1 (es) |
CO (1) | CO4910139A1 (es) |
CZ (1) | CZ98899A3 (es) |
EA (1) | EA001610B1 (es) |
HU (1) | HUP9904065A3 (es) |
ID (1) | ID21762A (es) |
IL (1) | IL128845A0 (es) |
NO (1) | NO991405L (es) |
PE (1) | PE27899A1 (es) |
PL (1) | PL332503A1 (es) |
TR (1) | TR199900651T2 (es) |
WO (1) | WO1998013027A1 (es) |
ZA (1) | ZA978517B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9922271D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
TWI275394B (en) * | 2000-01-26 | 2007-03-11 | Asahi Chemical Corp | Mizoribin tablet improved with color tone change |
US6740753B2 (en) | 2001-01-04 | 2004-05-25 | Geneva Pharmaceuticals, Inc. | Olanzapine crystal modification |
DE10232113A1 (de) * | 2002-07-16 | 2004-01-29 | Bayer Ag | Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel |
SI21303A (sl) * | 2002-10-18 | 2004-04-30 | Krka, Tovarna Zdravil, D.D.,, Novo Mesto | Farmacevtska formulacija olanzapina |
CA2510320C (en) | 2002-12-20 | 2012-10-09 | St. James Associates Llc/Faber Research Series | Coated particles for sustained-release pharmaceutical administration |
SI21402A (sl) | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
CN100563648C (zh) * | 2003-04-25 | 2009-12-02 | 田边三菱制药株式会社 | 包含亚烷基二氧苯衍生物的口服组合物 |
WO2005009407A2 (en) * | 2003-07-29 | 2005-02-03 | Ranbaxy Laboratories Limited | Oral pharmaceutical formulations of olanzapine |
US7829700B2 (en) | 2004-09-06 | 2010-11-09 | Shasun Chemicals And Drugs Limited | Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine |
CZ297214B6 (cs) * | 2005-02-02 | 2006-10-11 | Zentiva, A. S. | Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby |
WO2007049304A2 (en) * | 2005-10-27 | 2007-05-03 | Jubilant Organosys Limited | Stable coated pharmaceutical formulation of olanzapine and process for preparing the same |
ES2279715B1 (es) * | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
WO2007134845A2 (en) * | 2006-05-18 | 2007-11-29 | Synthon B.V. | Olanzapine pharmaceutical composition |
DE602006014030D1 (de) * | 2006-07-05 | 2010-06-10 | Bilim Ilac Sanayii Ve Ticaret | Stabile olanzapin-formulierung mit antioxidantien |
US20080138409A1 (en) * | 2006-09-29 | 2008-06-12 | Osinga Niels J | Olanzapine pharmaceutical composition |
EP2563763B1 (en) * | 2010-04-30 | 2014-12-31 | Bristol-Myers Squibb Company | Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide |
WO2012153347A2 (en) | 2011-05-04 | 2012-11-15 | Zentiva K.S. | Oral pharmaceutical composition of olanzapine form 1 |
SG11201507751YA (en) | 2013-03-21 | 2015-10-29 | Eupraxia Pharmaceuticals USA LLC | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith |
CN108289857A (zh) | 2015-10-27 | 2018-07-17 | 优普顺药物公司 | 局部麻醉药的持续释放制剂 |
CN107007559B (zh) * | 2017-04-21 | 2020-05-15 | 浙江京新药业股份有限公司 | 一种稳定的口服药物组合物及其制备方法 |
WO2019113084A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
SG11202005016SA (en) | 2017-12-05 | 2020-06-29 | Sunovion Pharmaceuticals Inc | Nonracemic mixtures and uses thereof |
KR20220018004A (ko) | 2019-06-04 | 2022-02-14 | 선오비온 파마슈티컬스 인코포레이티드 | 조절 방출 제형 및 이의 용도 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4820522A (en) * | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
US5605897A (en) * | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
ZA922777B (en) * | 1991-04-29 | 1993-10-15 | Lilly Co Eli | Pharmaceutical formulation containing dirithromycin |
JPH05194225A (ja) * | 1991-11-07 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | 安定化された抗潰瘍剤含有製剤 |
NZ247703A (en) * | 1992-05-29 | 1995-07-26 | Lilly Industries Ltd | Thienobenzdiazepine derivatives and medicaments thereof |
SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
US5637584A (en) * | 1995-03-24 | 1997-06-10 | Eli Lilly And Company | Solvate of olanzapine |
CR5278A (es) * | 1995-03-24 | 1996-07-04 | Lilly Co Eli | Formulacion oral de 2-metil-tieno-benzodiacepina |
EP0733368A1 (en) * | 1995-03-24 | 1996-09-25 | Eli Lilly And Company | Granule fomulation for olanzapine |
-
1997
- 1997-09-18 ID IDW990060A patent/ID21762A/id unknown
- 1997-09-18 CA CA002266448A patent/CA2266448A1/en not_active Abandoned
- 1997-09-18 IL IL12884597A patent/IL128845A0/xx unknown
- 1997-09-18 BR BR9713215-2A patent/BR9713215A/pt not_active IP Right Cessation
- 1997-09-18 CN CN97198099A patent/CN1230883A/zh active Pending
- 1997-09-18 CZ CZ99988A patent/CZ98899A3/cs unknown
- 1997-09-18 HU HU9904065A patent/HUP9904065A3/hu unknown
- 1997-09-18 JP JP10515724A patent/JP2001501207A/ja not_active Ceased
- 1997-09-18 PL PL97332503A patent/PL332503A1/xx unknown
- 1997-09-18 KR KR1019990702455A patent/KR20000048540A/ko not_active Application Discontinuation
- 1997-09-18 AU AU44230/97A patent/AU719788B2/en not_active Ceased
- 1997-09-18 WO PCT/US1997/016547 patent/WO1998013027A1/en not_active Application Discontinuation
- 1997-09-18 EA EA199900331A patent/EA001610B1/ru not_active IP Right Cessation
- 1997-09-18 TR TR1999/00651T patent/TR199900651T2/xx unknown
- 1997-09-22 CO CO97055063A patent/CO4910139A1/es unknown
- 1997-09-22 EP EP97307380A patent/EP0830858A1/en not_active Withdrawn
- 1997-09-22 ZA ZA978517A patent/ZA978517B/xx unknown
- 1997-09-23 PE PE1997000854A patent/PE27899A1/es not_active Application Discontinuation
- 1997-09-23 US US08/935,882 patent/US20010020032A1/en not_active Abandoned
- 1997-09-23 AR ARP970104363A patent/AR009802A1/es unknown
-
1999
- 1999-03-23 NO NO991405A patent/NO991405L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA199900331A1 (ru) | 2000-04-24 |
IL128845A0 (en) | 2000-01-31 |
US20010020032A1 (en) | 2001-09-06 |
AU719788B2 (en) | 2000-05-18 |
HUP9904065A3 (en) | 2001-10-29 |
WO1998013027A1 (en) | 1998-04-02 |
ZA978517B (en) | 1999-03-23 |
PL332503A1 (en) | 1999-09-13 |
BR9713215A (pt) | 2000-04-04 |
AR009802A1 (es) | 2000-05-03 |
CN1230883A (zh) | 1999-10-06 |
EA001610B1 (ru) | 2001-06-25 |
AU4423097A (en) | 1998-04-17 |
JP2001501207A (ja) | 2001-01-30 |
HUP9904065A2 (hu) | 2000-04-28 |
CA2266448A1 (en) | 1998-04-02 |
CZ98899A3 (cs) | 1999-12-15 |
TR199900651T2 (xx) | 1999-07-21 |
NO991405D0 (no) | 1999-03-23 |
ID21762A (id) | 1999-07-22 |
KR20000048540A (ko) | 2000-07-25 |
NO991405L (no) | 1999-03-23 |
EP0830858A1 (en) | 1998-03-25 |
PE27899A1 (es) | 1999-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4910139A1 (es) | Formulaciones en particulas revestidas | |
HUP9900231A2 (hu) | Szabályozott kibocsátású készítmények gyengén oldódó gyógyszerekhez | |
MX9804008A (es) | Formulaciones farmaceuticas. | |
YU36700A (sh) | Oralni farmaceutski oblik za doziranje sa produženim oslobađanjem | |
AR001405A1 (es) | Formulación oral de 2-metil-tieno-beno-diacepina. | |
IL150895A0 (en) | Oral, nasal and pulmonary formulations of copolymer-1 | |
DK1169024T3 (da) | Prægelatineret stivelse i en formulering med kontrolleret frigivelse | |
DE60121570D1 (de) | Oral anzuwendende schnell zerfallende feste darreichungsformen | |
IE970588A1 (en) | Controlled release pharmaceutical compositions containing tiagabine | |
BR9808888A (pt) | Formas de dosagem e método de melhorar disfunção erétil masculina | |
AR013117A1 (es) | Una composicion farmaceutica solida en forma de comprimido que comprende un derivado de benzofurano con actividad antiarritmica adaptada para administracion oral | |
ATE283708T1 (de) | Im mundraum schnellzerfallende tabletten | |
IS6209A (is) | Ný blanda | |
DK0793495T3 (da) | Frysetørrede ondansetronpræparater | |
KR900009071A (ko) | 점착성 제피정 | |
NZ332198A (en) | sustained release composition containing a gelling agent and 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]-dibenzo[b,f][1, 4]-thiazepine | |
HUP9901830A2 (hu) | Nefazodon dózisalak | |
HUP0104268A2 (hu) | Hosszan tartó hatóanyag-kibocsátású fluvasztatin-tartalmú gyógyászati készítmény | |
MY130332A (en) | Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer | |
Gajbhiye et al. | Comparative evaluation of three gingival displacement materials for efficacy in tissue management and dimensional accuracy | |
BR0014146A (pt) | Aparelho e método para anestesiar a região cervical de uma fêmea | |
AU2357202A (en) | Ion-strength independent sustained release pharmaceutical formulation | |
CA2417887A1 (en) | Particulate composition of eletriptan | |
CO5251412A1 (es) | Composicion farmaceutica de mirtazapina para administracion peroral con cubierta polimerica | |
MXPA02011533A (es) | Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona. |